Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma
Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma
Recruiting · NCT06569680 · Registry updated 2025-11-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma | Extranodal Marginal Zone Lymphoma | Recruiting | Phase 2 | 2025-11-03 | NCT06569680 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Genentech, Inc. | 221 |
| Izidore Lossos, MD | 2 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of Miami | Miami | United States | 327 |